In the small set of cases harboring molecular aberrations in EGFR and ALK included in this study, the null or heterogeneous p16Ink4A immunohistochemical expression conferred a poor prognosis, suggesting that the assessment of p16Ink4A protein status might help to tailor the prognostic evaluation of EGFR or ALK aberrant lung cancers. The gene discussed is CDKN2A; the disease is lung carcinoma.